Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* patients must sign informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.~* Patients must have a diagnosis of COPD and must meet the following spirometric criteria:~Patients must have relatively stable airway obstruction with a post-bronchodilator (10 to 45 minutes after 400mcg salbutamol) FEV1\>30% and \< 80% of predicted normal (ECSC, GOLD II - III) and a post-bronchodilator FEV1/FVC \<70% at Visit 1~* Male or female patients, 40 years of age or older.~* Patients must be current or ex-smokers with a smoking history of more than 10 pack years.~* Patients who have never smoked cigarettes must be excluded.~* Patients must be able to perform technically acceptable pulmonary function tests according to ATS/ERS guidelines and maintain records in a paper diary~* Patients must be able to inhale medication in a competent manner from the RESPIMAT inhaler and from a metered dose inhaler (MDI).~Exclusion criteria:~* Significant disease other than COPD~* Clinically relevant abnormal lab values.~* History of asthma.~* Diagnosis of thyrotoxicosis~* Diagnosis of paroxysmal tachycardia~* History of myocardial infarction within 1 year of screening visit~* Unstable or life-threatening cardiac arrhythmia~* Hospitalization for heart failure within the past year~* Known active tuberculosis~* Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~* History of life-threatening pulmonary obstruction and patients with chronic respiratory failure~* History of cystic fibrosis~* Clinically evident bronchiectasis~* History of significant alcohol or drug abuse~* Thoracotomy with pulmonary resection~* Patients treated with oral or patch ß-adrenergics~* Patients treated with oral corticosteroid medication at unstable doses or at doses in excess of 10mg prednisolone per day or equivalent~* Regular use of daytime oxygen therapy for more than one hour per day~* Pulmonary rehabilitation program in the six weeks prior to the screening visit or patients currently in a pulmonary rehabilitation program~* Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~* Known hypersensitivity to ß-adrenergic and/or anticholinergic drugs, BAC, EDTA~* Pregnant or nursing women~* Women of childbearing potential not using a highly effective method of birth control~* Patient who have previously been randomized in this study or are currently participating in another study~* Patients who are unable to comply with pulmonary medication restrictions prior to randomization

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium/Olodaterol FDC (Type: EXPERIMENTAL): patient will receive tiotropium and olodaterol in a fixed dose combination
- Tiotropium and Olodaterol FC (Type: EXPERIMENTAL): patient will receive tiotropium and olodaterol in a free combination
- Placebo (Type: PLACEBO_COMPARATOR): patient will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).